ATE340581T1 - Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe - Google Patents

Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe

Info

Publication number
ATE340581T1
ATE340581T1 AT97949716T AT97949716T ATE340581T1 AT E340581 T1 ATE340581 T1 AT E340581T1 AT 97949716 T AT97949716 T AT 97949716T AT 97949716 T AT97949716 T AT 97949716T AT E340581 T1 ATE340581 T1 AT E340581T1
Authority
AT
Austria
Prior art keywords
delayed
sustained release
vitamin
formulations
extended release
Prior art date
Application number
AT97949716T
Other languages
English (en)
Inventor
Charles W Bishop
Joyce C Knutson
Charles R Valliere
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Application granted granted Critical
Publication of ATE340581T1 publication Critical patent/ATE340581T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97949716T 1996-12-30 1997-12-10 Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe ATE340581T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/775,447 US5795882A (en) 1992-06-22 1996-12-30 Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations

Publications (1)

Publication Number Publication Date
ATE340581T1 true ATE340581T1 (de) 2006-10-15

Family

ID=25104456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97949716T ATE340581T1 (de) 1996-12-30 1997-12-10 Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe

Country Status (15)

Country Link
US (1) US5795882A (de)
EP (1) EP0951286B1 (de)
JP (1) JP2001512418A (de)
KR (1) KR20000062405A (de)
CN (1) CN100345547C (de)
AT (1) ATE340581T1 (de)
AU (1) AU724153B2 (de)
BR (1) BR9715022A (de)
CA (1) CA2276465A1 (de)
DE (1) DE69736745D1 (de)
HU (1) HUP0003526A2 (de)
MX (1) MXPA99006988A (de)
NZ (1) NZ336511A (de)
PL (1) PL334348A1 (de)
WO (1) WO1998029105A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) * 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
CA2279590A1 (en) * 1997-02-13 1998-08-20 Bone Care International, Inc. Targeted therapeutic delivery of vitamin d compounds
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU9376998A (en) * 1997-09-02 1999-03-22 Johns Hopkins University School Of Medicine, The Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6849616B1 (en) * 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
EP1064000B1 (de) 1998-03-27 2011-07-06 Oregon Health & Science University Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
AU2002228648A1 (en) * 2000-11-16 2002-05-27 Pharmacia And Upjohn Company Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
US20040071789A1 (en) * 2002-02-14 2004-04-15 Baron John A Calcium supplementation to reduce prostate cancer risk
US7129230B2 (en) * 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
MXPA04005260A (es) * 2001-12-03 2005-03-23 Novacea Inc Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.
US20080260834A1 (en) * 2002-08-20 2008-10-23 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US20040126318A1 (en) * 2002-09-12 2004-07-01 Ehrenpreis Eli D. Methods, formulations and kits for monitoring and diagnosing gastric emptying and gastroparesis, and formulations for determining gastrointestinal motility
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
JP2007501865A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンｄ化合物による癌の治療法
WO2005011660A1 (en) * 2003-07-29 2005-02-10 Abbott Laboratories Use of vitamin d to down regulate the renin-angiotensin-aldosterone system
EP1664784A1 (de) * 2003-09-17 2006-06-07 Guava Technologies, Inc. Zusammensetzungen und verfahren zur analyse von zielsubstanzen
JP2007506780A (ja) * 2003-09-24 2007-03-22 ビオエクセル エスピーエー 膀胱機能障害の治療方法
US7332482B2 (en) * 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
CA2586679A1 (en) * 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
CA2924200C (en) * 2005-10-12 2017-09-05 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
EP1968383B1 (de) * 2005-12-12 2011-05-11 Women and Infants Hospital of Rhode Island Derivate von vitamin d und ihre verwendung in der therapie
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
PT3357496T (pt) 2006-06-21 2020-05-12 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
CN101668532B (zh) * 2007-04-25 2014-08-20 赛特克罗公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途
PL3225243T3 (pl) 2007-04-25 2025-12-22 Opko Renal, Llc Sposób bezpiecznego i skutecznego leczenia i zapobiegania wtórnej nadczynności przytarczyc w przewlekłej chorobie nerek
US8592401B2 (en) * 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
KR20190141269A (ko) 2007-04-25 2019-12-23 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
US20100158998A1 (en) * 2008-12-23 2010-06-24 Michael Fox Formulations comprising vitamin d or derivatives thereof
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103142537B (zh) * 2013-03-21 2014-11-12 青岛正大海尔制药有限公司 骨化三醇缓释剂片
CN103142555B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种阿法骨化醇缓释胶囊及其制备方法
CN103142554B (zh) * 2013-03-21 2014-11-12 青岛正大海尔制药有限公司 骨化三醇控释胶囊及其制备方法
CN103142553B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种骨化三醇缓释胶囊及其制备方法
JP6282939B2 (ja) * 2014-06-05 2018-02-21 株式会社ファンケル 耐酸性錠剤
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP4596045A3 (de) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Verfahren zur behandlung von vitamin d
KR102121400B1 (ko) * 2018-07-31 2020-06-17 (주)에이치케이바이오텍 신령버섯균사체 액체배양 추출물을 포함하는 전립선 비대증의 예방 또는 치료용 조성물
MX2020011740A (es) 2018-08-31 2021-04-19 Opko Ireland Global Holdings Ltd Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso.
IT201900003843A1 (it) * 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
CN110917169A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 帕立骨化醇胶囊剂及其制备方法
CN110917163A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 一种帕立骨化醇固体口服制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2216719A (en) * 1935-07-06 1940-10-08 Hartford Nat Bank & Trust Co Vitamin
US2434015A (en) * 1942-11-21 1948-01-06 Du Pont Stable provitamin d composition
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
DE3270978D1 (en) * 1981-07-17 1986-06-12 Duphar Int Res Method of preparing 1-alpha-hydroxyvitamin d and 1-alpha-hydroxy-previtamin d compounds, and adduct of a previtamin d or tachysterol compound with a suitable dienophile
JPS5910562A (ja) * 1982-07-07 1984-01-20 Teijin Ltd プレ−１α−ヒドロキシコレカルシフエロ−ル類の製造法
DE3490215C2 (de) * 1983-05-09 1991-07-25 Wisconsin Alumni Res Found
US4505906A (en) * 1984-01-30 1985-03-19 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 isomers
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
GB2183156B (en) * 1985-03-14 1989-06-21 Chugai Pharmaceutical Co Ltd Composition for treating skin disease
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
WO1990009179A1 (en) * 1989-02-16 1990-08-23 University Of Georgia Research Foundation, Inc. Treatment of tibial dyschondroplasia
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
IL110117A0 (en) * 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
DK0832063T3 (da) * 1995-06-14 2000-06-13 Schering Ag Vitamin D-derivater med substituenter på C-25, fremgangsmåde til deres fremstilling, mellemprodukter samt deres anvendelse

Also Published As

Publication number Publication date
CN1251527A (zh) 2000-04-26
DE69736745D1 (de) 2006-11-09
EP0951286B1 (de) 2006-09-27
EP0951286A2 (de) 1999-10-27
MXPA99006988A (es) 2002-07-02
NZ336511A (en) 2001-08-31
AU724153B2 (en) 2000-09-14
CA2276465A1 (en) 1998-07-09
WO1998029105A3 (en) 1998-10-15
JP2001512418A (ja) 2001-08-21
BR9715022A (pt) 2001-09-18
CN100345547C (zh) 2007-10-31
AU7888398A (en) 1998-07-31
PL334348A1 (en) 2000-02-28
KR20000062405A (ko) 2000-10-25
US5795882A (en) 1998-08-18
WO1998029105A2 (en) 1998-07-09
HUP0003526A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
BR0008397A (pt) Processos para acentuar a absorção celular de uma substância suprida para dentro de uma região alvo do corpo de um paciente, para acentuar a transfecção de dna suprido para dentro de uma região alvo do corpo de um paciente, e para inibir hiperplasia ìntima vascular, sistema de suprimento de energia de ultra-som de campo uniforme e feixe largo, conjuntos para acentuar a absorção celular de uma substância suprida para dentro de uma região alvo do corpo de um paciente, para acentuar a transfecção de dna suprido para dentro de uma região alvo do corpo de um paciente, e para inibir hiperplasia ìntima vascular, e, sistema de suprimento de energia de ultra-som de campo uniforme e feixe largo
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DE69309701D1 (de) Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung periodontaler erkrankungen
ATE296097T1 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung kolorektales krebs
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
DK0731699T3 (da) Fremgangsmåde til reduktion af legemsfedt i dyr ved indgivelse af konjugeret linolsyre
ATE369817T1 (de) Vorrichtung zur abgabe von therapeutischen wirkstoffen
PT946151E (pt) Forma de dosagem de dose crescente
ES2171933T3 (es) Derivados de androsteno.
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE59508360D1 (de) Liposomal verkapseltes taxol, seine herstellung und seine verwendung
DE60035574D1 (de) Formulierungen zur behandlung von krankheiten und verfahren unter deren verwendung
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DE69914084D1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
BG105275A (en) Tan-1057 derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties